Hepatitis C treatment gap in Europe: France doing well but Italy treated fewer than one in a hundred patients in 2010
Triple therapy for hepatitis C is effective after liver transplantation, but side-effects are common
Movement for global access to hepatitis C treatment building momentum
Daclatasvir + asunaprevir + BMS-791352 looks promising as interferon-free combination
Compassionate access to new hepatitis C drugs an "emergency" for European patients
Second-generation HCV protease inhibitor simeprevir pushes triple therapy cure rate up to 80%
Second-generation protease inhibitor faldaprevir cures up to 80% of hepatitis C
Triple-drug HCV therapy comes with high risk of serious adverse events for people with cirrhosis
Hep C quad regimens quashed, but some components go forward
Daclatasvir + sofosbuvir offers hepatitis C rescue therapy after current standard of care
AbbVie interferon-free combination cures over 90% of hepatitis C genotype 1
Sofosbuvir + ribavirin cures most genotype 2 hepatitis C, but genotype 3 response is lower
